NeoDynamics AB announced the appointment of current board member Matt Colpoys as head of the company's US subsidiary. Colpoys will remain on the board and will report to CEO Anna Eriksrud. Mr. Colpoys has over 35 years' experience in the biopharmaceutical/medtech industry. Most recently he founded and led Tactiva Therapeutics Inc., an Immuno-Oncology start up, through their $35M Series A fund raise. He was a key member of the early commercial and management teams at Genentech (Sold to Roche), Pharmacia (Sold to Pfizer), Neurex (Sold to Elan) and Insmed. At these companies his integral participation resulted in a number of successful commercial product
launches, two of which resulted in products currently selling in excess of $300M (US). As President of Galileo Consulting, a global biopharmaceutical advisory and consulting practice, he has assisted a wide range of companies in
their business development, strategic planning, fundraising and M&A activities.